News About: Pharm. Industry
Hanmi’s legend of KRW 6 trillion technology export achieved by R&D
The reason why it was possible for Hanmi Pharm to export the new technology worth of KRW 6 trillion, which rarely happens even in the global market, was evaluated as its effort into endless investments in R&D.
While ...
Sales and profits of Hanmi and Huons fly in respective KOSPI and KOSDAQ
As a pharmaceutical company, Hanmi Pharm and Huons have made a rush in the KOSPI and KOSDAQ, respectively.
It was analyzed, particularly, 53 listed pharmaceutical companies recorded double-digit growth rates of avera...
Candidate companies to join in KRW 1 Trillion Sales ClubAfter Yuhan Corporation entered the KRW 1 trillion sales club for the first time in the pharmaceutical company last year, second and third candidate companies which may join in ...
|
48 lawsuits against Brilinta patent only in 15 days
Generics of Brilinta(AstraZeneca, ticagrelor), which has been recognized as a next-generation antithrombotic agent followed by Aspirin and Plavix, have attracted vigorous interests of domestic pharmaceutical companie...
3rd quarter’s decent performance of 41 listed pharmaceutical companies
Domestic pharmaceutical companies have made decent performance even in the MERS crisis.
According to the data aggregated from 41 listed pharmaceutical companies which published 3rd quarter’s tentative performance by ...
Hanmi Pharm launches complex treatment of rosuvastatin and ezetimibeHanmi Pharm(CEO Kwan-soon Lee) launched ‘Rosuzet,’ a complex drug combining ‘rosuvastatin,’ a substance of hyperlipidemia treatment, and ‘ezetimibe’ for the first time in the wo...
|
The only Priligy generic by Shin Poong, given up by mostWhen it comes to Priligy(dapoxetine hydrochloride), a male premature ejaculation treatment which caused issues with patent lawsuits, the pharmaceutical industry has shown much l...
|
Cesentyx becomes a new psoriasis treatment optionThe industry has attracted attention if Novartis’s Cosentyx(generic name: secukinumab) will deliver a new treatment option to severe psoriasis patients.
Last September, Novarti...
|
Celltrion applied for European approval of biosimilar antibody for the second timeOn the 11th, Celltion announced the European Medicines Agency(EMA) received the document for the approval application of CT-P10 on the 10th of November(local time).
Since the c...
|
Winning of the Feburic patent trial neutralized sales prohibition of genericsAs companies which sell generics of ‘Feburic Tab(SK Chemicals, febuxostat),’ a gout treatment, won the patent suit, they neutralized the sales prohibition action. Thus, commerci...
|
